‼️High Dose semaglutide #wegovy now recommend for the management of #obesity in 🇬🇧‼️
✅@NICEComms
https://t.co/oLhaPTANH0
📍2.4mg semaglutide ⤵️ weight by 12.4% over 68 weeks
📍50.5% of people ⤵️ weight by 15%
Check out our video the effectiveness
👇👇👇
1) Welcome to a new #accredited#tweetorial on the latest advances in the management of #CKD in the setting of patients with and without #T2D--this time with a hot-off-the-presses update from #ASN22#KIDNEYWEEK2022: eagerly-awaited results of the #EMPA_KIDNEY trial.
Daprodustst got mixed results from its advisory committee meeting. Panel voted no for non-dialysis, yes for dialysis in renal anemia.
The need for an oral drug such as this is stronger in the non-dialysis population. $GSK
The very brilliant @DrStuartFlint speaking now at #BOMSS22. Have learned so much about obesity stigma from him and always learn something new when he talks.
▶️▶️Preventing and delaying cardiorenal disease
⚠️ #DELIVER, with #HFpEF & #HFmrEF (n=6,263), has met its primary endpoint (CV death + worsening HF)
📍 https://t.co/6lzv6QqtLK @secardiologia@IcyfaSemi
Don’t let your typo cause a hypo, take care with look-a-like 👀 sound-a-like 👂 insulins 💉
Make sure you know your Humalog from your Humalog Mix25, your Humulin I from your Humulin M3
If I’m doubt double check and ask a member of the pharmacy team 👍
#InsulinSafetyWeek2022
P3 #EMPAKIDNEY RCT stopped early due to efficacy in #CKD. Congrats @willkidney@Oxford_NDPH & investigators!
Broad clinical profiles
⭐️1/2 w/o diabetes
⭐️1/2 w/ UACR<300mg/g
⭐️1/4 w/ GN
CKD trials likely to have clearest mortality signal across #CaReMe.
https://t.co/Atj9Yx9VN0
In honor of #WorldKidneyDay today, the ISN has dressed the famous #MannekenPis with the colors of @WorldKidneyDay. Special thanks to the city of Brussels for helping us to raise awareness of the high burden of kidney disease worldwide.
Madrigal's resmetirom.
MAESTRO-NAFLD-1 placebo arm liver fat change of +8 or -8%?🧐 Makes a massive difference to active arm efficacy.
Its being reported differently within Madrigal and the specialist media.
I'm assuming its -8%. Did $MDGL post a correction? #NASH
1) Welcome to a new #accredited#tweetorial on currently available treatments for mineralocorticoid receptor (MR) antagonism (#MRA), the differences among them, and how these differences impact on treatment of cardio-reno-metabolic diseases #CaReMe#FOAMed
EMPULSE trial. The fact that enrollment was irrespective of diabetes is another step toward SGLT-2 inhibitors being recognized as cardiovascular treatments in addition to the type 2 diabetes therapies they were originally developed as. #aha21#heartfailure https://t.co/uYn0GTB9Vh